As CKD progresses, compensation for the elevations of PTH and FGF-23 as well as the decreased levels of 1,25(OH)2D3 becomes inadequate, resulting in hyperphosphatemia, hypocalcemia, abnormal bone disorders, and extra-skeletal calcification. This evidence concerns the gene FGF23 and hyperphosphatemia.